CO2019013196A2 - Anticuerpos humanos contra bet v 1 y métodos de uso de los mismos - Google Patents
Anticuerpos humanos contra bet v 1 y métodos de uso de los mismosInfo
- Publication number
- CO2019013196A2 CO2019013196A2 CONC2019/0013196A CO2019013196A CO2019013196A2 CO 2019013196 A2 CO2019013196 A2 CO 2019013196A2 CO 2019013196 A CO2019013196 A CO 2019013196A CO 2019013196 A2 CO2019013196 A2 CO 2019013196A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- bet
- methods
- fagales
- allergens
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000013566 allergen Substances 0.000 abstract 4
- 241000219427 Fagales Species 0.000 abstract 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract 2
- 210000003651 basophil Anatomy 0.000 abstract 2
- 210000003630 histaminocyte Anatomy 0.000 abstract 2
- 235000018185 Betula X alpestris Nutrition 0.000 abstract 1
- 235000018212 Betula X uliginosa Nutrition 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229960001340 histamine Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
En el presente documento se proporcionan anticuerpos que se unen a alérgenos de Fagales, alérgenos relacionados con Fagales, polen de abedul o Bet v 1, composiciones que comprenden los anticuerpos, ácidos nucleicos que codifican los anticuerpos y métodos para usar los anticuerpos. Según ciertas formas de realización, los anticuerpos son anticuerpos monoclonales completamente humanos que se unen a Bet v 1. Los anticuerpos son útiles para unirse Bet v 1 in vivo, evitando así la unión del alérgeno a la IgE preformada sobre la superficie de los mastocitos o basófilos. Al hacerlo, los anticuerpos actúan para prevenir la liberación de histamina y otros mediadores inflamatorios desde los mastocitos y/o basófilos, mejorando así la respuesta desfavorable a los alérgenos de Fagales en individuos sensibilizados.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513872P | 2017-06-01 | 2017-06-01 | |
| US201762571696P | 2017-10-12 | 2017-10-12 | |
| US201862662165P | 2018-04-24 | 2018-04-24 | |
| PCT/US2018/035366 WO2018222854A1 (en) | 2017-06-01 | 2018-05-31 | Human antibodies to bet v 1 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019013196A2 true CO2019013196A2 (es) | 2020-01-17 |
Family
ID=62705709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0013196A CO2019013196A2 (es) | 2017-06-01 | 2019-11-26 | Anticuerpos humanos contra bet v 1 y métodos de uso de los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10793624B2 (es) |
| EP (1) | EP3630814A1 (es) |
| JP (3) | JP6963036B2 (es) |
| KR (3) | KR20240096746A (es) |
| CN (1) | CN110997713B (es) |
| AU (2) | AU2018275657B2 (es) |
| BR (1) | BR112019025150B1 (es) |
| CA (1) | CA3063588A1 (es) |
| CL (3) | CL2019003508A1 (es) |
| CO (1) | CO2019013196A2 (es) |
| IL (2) | IL298034B2 (es) |
| MX (2) | MX2019014430A (es) |
| NZ (1) | NZ759513A (es) |
| PH (1) | PH12019550238A1 (es) |
| WO (1) | WO2018222854A1 (es) |
| ZA (1) | ZA201907513B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298034B2 (en) * | 2017-06-01 | 2024-05-01 | Regeneron Pharma | Antibodies against BET V 1 and methods of using them |
| EP4175986A1 (en) | 2020-07-01 | 2023-05-10 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-bet v 1 antibodies |
| CN113041271B (zh) * | 2021-04-14 | 2022-12-27 | 浙江养生堂天然药物研究所有限公司 | 具有预防和抗过敏功效的组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5411594A (en) | 1992-10-27 | 1994-05-24 | Biomay Produktions- Und Handelsgesellschaft M.B.H. | Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order |
| WO1994014475A1 (en) | 1992-12-21 | 1994-07-07 | Tanox Biosystems, Inc. | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT |
| EP0619323A1 (en) | 1993-04-09 | 1994-10-12 | Schering-Plough | Human monoclonal antibodies and processes and materials for making such antibodies |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| ITMI20052517A1 (it) * | 2005-12-29 | 2007-06-30 | Lofarma Spa | Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa |
| AT503297B1 (de) | 2006-05-18 | 2007-09-15 | Biomay Ag | Allergen-spezifische antikörper |
| DK2374818T3 (da) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
| GB201002559D0 (en) | 2010-02-15 | 2010-03-31 | Circassia Ltd | Birch peptides for vaccine |
| US10935554B2 (en) | 2013-08-23 | 2021-03-02 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT) |
| IL298034B2 (en) | 2017-06-01 | 2024-05-01 | Regeneron Pharma | Antibodies against BET V 1 and methods of using them |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
-
2018
- 2018-05-31 IL IL298034A patent/IL298034B2/en unknown
- 2018-05-31 AU AU2018275657A patent/AU2018275657B2/en active Active
- 2018-05-31 US US15/994,294 patent/US10793624B2/en active Active
- 2018-05-31 EP EP18733431.3A patent/EP3630814A1/en active Pending
- 2018-05-31 MX MX2019014430A patent/MX2019014430A/es unknown
- 2018-05-31 JP JP2019565912A patent/JP6963036B2/ja active Active
- 2018-05-31 CN CN201880049949.7A patent/CN110997713B/zh active Active
- 2018-05-31 KR KR1020247018848A patent/KR20240096746A/ko unknown
- 2018-05-31 IL IL270894A patent/IL270894B2/en unknown
- 2018-05-31 BR BR112019025150-2A patent/BR112019025150B1/pt active IP Right Grant
- 2018-05-31 WO PCT/US2018/035366 patent/WO2018222854A1/en active Application Filing
- 2018-05-31 CA CA3063588A patent/CA3063588A1/en active Pending
- 2018-05-31 KR KR1020197036599A patent/KR102329175B1/ko active IP Right Grant
- 2018-05-31 NZ NZ759513A patent/NZ759513A/en unknown
- 2018-05-31 KR KR1020217037411A patent/KR102674000B1/ko active IP Right Grant
-
2019
- 2019-11-13 ZA ZA2019/07513A patent/ZA201907513B/en unknown
- 2019-11-14 PH PH12019550238A patent/PH12019550238A1/en unknown
- 2019-11-26 CO CONC2019/0013196A patent/CO2019013196A2/es unknown
- 2019-11-29 CL CL2019003508A patent/CL2019003508A1/es unknown
- 2019-11-29 MX MX2023000390A patent/MX2023000390A/es unknown
-
2020
- 2020-08-28 US US17/006,599 patent/US11767358B2/en active Active
-
2021
- 2021-04-27 JP JP2021074862A patent/JP7162097B2/ja active Active
- 2021-10-29 CL CL2021002851A patent/CL2021002851A1/es unknown
- 2021-10-29 CL CL2021002850A patent/CL2021002850A1/es unknown
-
2022
- 2022-01-17 AU AU2022200272A patent/AU2022200272A1/en active Pending
- 2022-09-15 JP JP2022146982A patent/JP7458453B2/ja active Active
-
2023
- 2023-08-09 US US18/232,238 patent/US20240083986A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002851A1 (es) | Anticuerpos humanos contra bet v 1 o extracto de polen de abedul; composición farmacéutica que los comprende; y métodos de uso de los mismos (divisional de la solicitud 201903508) | |
| AR090914A1 (es) | Anticuerpos humanos para fel d1 y metodos para usarlos | |
| EA201600618A1 (ru) | Устройство для рассеяния энергии | |
| UY36538A (es) | Anticuerpos humanos contra la glicoproteína del virus del ébola | |
| CR20150405A (es) | Anticuerpos anti-il-17a y su uso en el tratamiento de transtornos autoinmunes e inflamatorios | |
| AR090585A1 (es) | Anticuerpos anti-hla-b*27 y usos de estos | |
| CR20150437A (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
| CL2019000019A1 (es) | Anticuerpos con baja inmunogenicidad y uso de los mismos | |
| CU20210041A7 (es) | Péptidos inmunogénicos con motivos de oxidorreductasa | |
| WO2014080154A8 (en) | A deformable element | |
| AR117721A2 (es) | Anticuerpos humanos para fel d1 y métodos para usarlos | |
| EA201992651A1 (ru) | АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| AR087330A1 (es) | Fago modificado geneticamente y uso del mismo | |
| ES2613586B2 (es) | Partículas purificadas de polen, procedimiento y su uso para administrar nanosistemas | |
| NO20160945A1 (en) | Exercising device | |
| TH180929A (th) | แอนติ-ทรานสเฟอริน รีเซพเตอร์ แอนติบอดีที่มีอาฟฟินิตี้ที่ถูกปรับให้เหมาะสม | |
| RU2017132096A (ru) | Применение липополисахарида rhodobacter capsulatus pg в качестве противоаллергического средства | |
| TH1701003675A (th) | ส่วนประกอบที่นั่งยานพาหนะและวิธีการผลิตของมัน | |
| TH182888A (th) | โคพอลิเมอร์ของไบไซคลิค(เมธ)อะคริเลท และแอลคิล(เมธ)อะคริเลท และการใช้ของสารเหล่านั้นเป็นสารดัดแปรรีโอโลยีในเชื้อเพลิง | |
| TH1801000535A (th) | โครงสร้างแอนติบอดีที่มีความจำเพาะแบบคู่ที่จับdll3และcd3 | |
| TH1701004813A (th) | แอนติบอดีต่อเทาและการใช้สิ่งดังกล่าว | |
| TH68690B (th) | เครื่องทดสอบการเลี้ยวเบนของรังสีเอกซ์ และวิธีการวัดค่าการเลี้ยวเบนของรังสีเอกซ์ | |
| TH1701004686A (th) | ระบบสเปกโตรสโคปีแบบโฟโตเทอร์มัลสำหรับการทดสอบซิงโครไนซ์แบบออฟเซ็ตของตัวทดสอบการไหลและวิธีการใช้สิ่งดังกล่าว | |
| TH180367A (th) | แอนติ-il-13/il- 17 ไบสเปซิฟิก แอนติบอดี และการใช้ของมัน | |
| TH168763A (th) | ยีสต์ที่มีความสามารถในการหมักไซโลสที่ดีขึ้นและการใช้ยีสต์นี้ |